Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials

PurposeTo investigate the role of baseline demographics, disease characteristics, and treatment responses to ranibizumab during RIDE/RISE in predicting long-term treatment frequency with a criteria-based pro re nata (PRN) regimen during the open-label extension (OLE).DesignPooled, retrospective, post hoc analysis from the phase III, randomized RIDE/RISE studies and subsequent OLE.ParticipantsFive hundred patients enrolled in the OLE after...